Abstract: The invention relates to the use of a compound(s) selected from isoniazid and isoniazid analogs of formula Ia, wherein R is —C(O)NHNH2, —C(O)NHNHC1-6 alkyl, —C(O)NHN?C1-6 alkenyl, —C(O)NHNHC2-6 alkenyl, —C(O)NHC1-6 alkyl, —C(O)NHC2-6 alkenyl, —C(O)NHNHC(O)C1-6alkyl, —NHC(O)C1-6 alkyl, —NHC(O)C1-6 alkenyl, —NHC(O)NH2, —NHC(O)NHC1-6alkyl, —NHC(O)NHC2-6 alkenyl, or —COOH, and wherein formula (Ia) optionally is further substituted with one or more substituents; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the preparation of a pharmaceutical composition for treating a condition selected from the group consisting of cutaneous lesions, wounds, ulcers and infarcts in a tissue area with compromised vascularisation, in an animal, such as a human subject.